within Pharmacolibrary.Drugs.ATC.A;

model A03FA07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.0003383333333333334,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0060999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009233333333333335,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A03FA07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Itopride is a prokinetic agent, acting as a dopamine D2 receptor antagonist and acetylcholinesterase inhibitor, primarily used for the treatment of gastrointestinal motility disorders such as functional dyspepsia. It is currently approved and used in several countries, particularly in Asia, but not in the United States or Europe.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Sahoo, BK, Das, A, Agarwal, S, Bhaumik, U, Bose, A, Ghosh, D, Roy, B, &amp; Pal, TK (2009). Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers. <i>Arzneimittel-Forschung</i> 59(9) 451–454. DOI:<a href=\"https://doi.org/10.1055/s-0031-1296424\">10.1055/s-0031-1296424</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19856792/\">https://pubmed.ncbi.nlm.nih.gov/19856792</a></p></li><li><p>Yoon, S, Lee, H, Kim, TE, Lee, S, Chee, DH, Cho, JY, Yu, KS, &amp; Jang, IJ (2014). Comparative steady-state pharmacokinetic study of an extended-release formulation of itopride and its immediate-release reference formulation in healthy volunteers. <i>Drug design, development and therapy</i> 8 123–128. DOI:<a href=\"https://doi.org/10.2147/DDDT.S53027\">10.2147/DDDT.S53027</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24470753/\">https://pubmed.ncbi.nlm.nih.gov/24470753</a></p></li><li><p>Mushiroda, T, Douya, R, Takahara, E, &amp; Nagata, O (2000). The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: comparison with cisapride and mosapride citrate. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 28(10) 1231–1237. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10997945/\">https://pubmed.ncbi.nlm.nih.gov/10997945</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A03FA07;
